Aegerion’s Juxtapid Needs Long-term Post-Market Cohort Study After FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsor will institute a registry to monitor patients taking the LDL cholesterol-lowering drug for homozygous familial hypercholesterolemia for 10 years, as part of an approval that is a likely template for Genzyme’s Kynamro.